N·BIO | Noulin | BioConsulting

ADULT SNAPSHOT

Adult vaccination policy across 6 countries

Age, clinical risk and vaccination history shape the offer

Selected programmes | Adults 18+ | National baseline | 17 November 2026

Programme selected adult offers	France NATIONAL POLICY	England NATIONAL POLICY	Germany NATIONAL POLICY	Spain NATIONAL POLICY	Italy NATIONAL POLICY	USA NATIONAL POLICY
Influenza annual / seasonal	**65+; annual** risk + pregnancy	**65+; annual** risk + pregnancy	**60+; annual** risk + pregnancy	**60+; annual** risk + pregnancy	**60+; annual** risk + pregnancy	**18+; annual** all adults
COVID-19 season-specific	**65+; seasonal** risk + pregnancy	**75+; autumn** care homes / immune	**75+; annual** risk / occupation	**70+; seasonal** risk + pregnancy	**60+; seasonal** risk + pregnancy	**18+; 2026–27** Individual decision; dose varies
RSV older adults / risk	**75+; one dose** 65+ heart / lung risk	**75+; one dose** 65–74 specific risks[1]	**75+; one dose** 60–74 severe risk[2]	**18+ very high risk** 60+ eligible residences[3]	**Regional offers** No uniform national offer identified	**75+; one dose** 50–74 increased risk
Pneumococcal product & history	**65+; PCV20/21** 18+ risk; history	**65; PPV23 or PCV20** younger at risk	**60+; PCV20** younger at risk	**65+; conjugate** risk / local product	**65-year cohort** PCV ± PPSV23	**50+; 19–49 at risk[4]** PCV15 → PPSV23 if indicated or PCV20 / PCV21
Herpes zoster cohort / risk	**65+; 2 doses** 18+ immune risk	**65 phased cohort; 70–79** 18+ severe immune[5]	**60+; 2 doses** 50+ if at risk	**65; 2 doses** catch-up / risk	**65-year cohort** 1–2; product-specific	**50+; 2 doses** 19+ immune risk
Td / Tdap booster strategies	**25, 45, 65** then every 10 y	**Complete 5 doses** extra: wound / travel	**Td every 10 y** one adult Tdap	**Complete 5 doses** Td around 65	**dTpa every 10 y** pregnancy: each	**Td/Tdap every 10 y** ≥1 Tdap; pregnancy

[1] England: 65–74 with immunosuppression or specified chronic respiratory disease; older-adult care-home residents also eligible.
[2] Germany: 60–74 with severe qualifying conditions or care-home residence. [3] Spain: phased regional implementation.
[4] USA age 18 follows the child schedule. [5] England shingles: age 65 eligibility phased from Sep 2023; history and cohorts apply.

PREGNANCY AND RISK

Influenza and pertussis are offered in pregnancy across these programmes; timing and COVID-19 policy differ. Maternal RSV can protect infants in selected programmes; Germany prioritises infant antibody prophylaxis.

READING THE MATRIX

Age is a programme entry point, not a personal due date. Review prior doses, clinical risk and local eligibility. Italy: RSV provision varies by region. England: shingles and pneumococcal product transitions depend on policy.

Main takeaway

Similar pathogens, different adult vaccination strategies

Age thresholds, risk groups, pregnancy and delivery rules vary.

Sources: SPF • UKHSA • RKI • Sanidad • Salute • CDC; see notes

SOURCE CHECKED • 2026